Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment

BACKGROUND AND AIMS: Fasiglifam, a potent, selective novel agonist of G protein-coupled receptor 40, stimulates insulin secretion at elevated blood glucose levels in a glucose-dependent manner. This study evaluated the potential effect of hepatic impairment on the pharmacokinetics and safety of a si...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcinak, John, Vakilynejad, Majid, Kogame, Akifumi, Tagawa, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995786/
https://www.ncbi.nlm.nih.gov/pubmed/29488154
http://dx.doi.org/10.1007/s40268-018-0229-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995786/
https://www.ncbi.nlm.nih.gov/pubmed/29488154
http://dx.doi.org/10.1007/s40268-018-0229-9

Ejemplares similares